TY  - JOUR
AU  - Almanza-Aguilera, Enrique
AU  - Martínez-Huélamo, Miriam
AU  - López-Hernández, Yamilé
AU  - Guiñón-Fort, Daniel
AU  - Guadall, Anna
AU  - Cruz, Meryl
AU  - Perez-Cornago, Aurora
AU  - Rostgaard-Hansen, Agnetha L
AU  - Tjønneland, Anne
AU  - Dahm, Christina C
AU  - Katzke, Verena
AU  - Schulze, Matthias B
AU  - Masala, Giovanna
AU  - Agnoli, Claudia
AU  - Tumino, Rosario
AU  - Ricceri, Fulvio
AU  - Lasheras, Cristina
AU  - Crous-Bou, Marta
AU  - Sánchez, Maria-Jose
AU  - Aizpurua-Atxega, Amaia
AU  - Guevara, Marcela
AU  - Tsilidis, Kostas K
AU  - Chatziioannou, Anastasia Chrysovalantou
AU  - Weiderpass, Elisabete
AU  - Travis, Ruth C
AU  - Wishart, David S
AU  - Andrés-Lacueva, Cristina
AU  - Zamora-Ros, Raul
TI  - Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case-Control Analysis Within the EPIC Study.
JO  - Cancers
VL  - 16
IS  - 23
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2024-02728
SP  - 4116
PY  - 2024
AB  - Background and Objective: Nutrimetabolomics may reveal novel insights into early metabolic alterations and the role of dietary exposures on prostate cancer (PCa) risk. We aimed to prospectively investigate the associations between plasma metabolite concentrations and PCa risk, including clinically relevant tumor subtypes. Methods: We used a targeted and large-scale metabolomics approach to analyze plasma samples of 851 matched PCa case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Associations between metabolite concentrations and PCa risk were estimated by multivariate conditional logistic regression analysis. False discovery rate (FDR) was used to control for multiple testing correction. Results: Thirty-one metabolites (predominately derivatives of food intake and microbial metabolism) were associated with overall PCa risk and its clinical subtypes (p < 0.05), but none of the associations exceeded the FDR threshold. The strongest positive and negative associations were for dimethylglycine (OR = 2.13; 95
KW  - EPIC (Other)
KW  - nested case–control (Other)
KW  - nutrimetabolomics (Other)
KW  - prostate cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39682302
DO  - DOI:10.3390/cancers16234116
UR  - https://inrepo02.dkfz.de/record/295915
ER  -